Automotive Holiday Deals Up to 50% Off Select Books Shop Men's Athletic Shoes Learn more nav_sap_SWP_6M_fly_beacon Train egg_2015 All-New Amazon Fire TV Grocery Gifts for Her Amazon Gift Card Offer cm15 cm15 cm15 $30 Off Amazon Echo $30 Off Fire HD 6 Kindle Cyber Monday Deals Indie for the Holidays in Prime Music Shop Now HTL

Enter your mobile number or email address below and we'll send you a link to download the free Kindle App. Then you can start reading Kindle books on your smartphone, tablet, or computer - no Kindle device required.

  • Apple
  • Android
  • Windows Phone
  • Android

To get the free app, enter your email address or mobile phone number.

Science Business: The Promise, the Reality, and the Future of Biotech 1st Edition

13 customer reviews
ISBN-13: 978-1591398400
ISBN-10: 1591398401
Why is ISBN important?
This bar-code number lets you verify that you're getting exactly the right version or edition of a book. The 13-digit and 10-digit formats both work.
Scan an ISBN with your phone
Use the Amazon App to scan ISBNs and compare prices.
Have one to sell? Sell on Amazon
Buy used On clicking this link, a new layer will be open
$14.95 On clicking this link, a new layer will be open
Buy new On clicking this link, a new layer will be open
$23.93 On clicking this link, a new layer will be open
More Buying Choices
22 New from $11.50 35 Used from $0.33 2 Collectible from $11.99
Free Two-Day Shipping for College Students with Amazon Student Free%20Two-Day%20Shipping%20for%20College%20Students%20with%20Amazon%20Student

Get Up to 80% Back Rent Textbooks
$23.93 FREE Shipping on orders over $35. Temporarily out of stock. Order now and we'll deliver when available. We'll e-mail you with an estimated delivery date as soon as we have more information. Your account will only be charged when we ship the item. Ships from and sold by Gift-wrap available.

Frequently Bought Together

  • Science Business: The Promise, the Reality, and the Future of Biotech
  • +
  • The Billion Dollar Molecule: One Company's Quest for the Perfect Drug
  • +
  • From Alchemy To Ipo: The Business Of Biotechnology
Total price: $53.58
Buy the selected items together

Special Offers and Product Promotions

  • Take an Extra 30% Off Any Book: Use promo code HOLIDAY30 at checkout to get an extra 30% off any book for a limited time. Excludes Kindle eBooks and Audible Audiobooks. Restrictions apply. Learn more | Shop now

Editorial Reviews


"Pisano argues that as a business, the biotech sector hasn't matched the innovations of its science." -- BusinessWeek Online, December 20, 2006

"Science Business" provides a fascinating history of pharmaceuticals and biotechnology. -- The Wall Street Journal, January 3, 2007

From the Back Cover

"A very insightful analysis of the remarkable evolution of the biotech industry. This is required reading for all involved in this process, biotechnology entrepreneurs, venture capitalists, academics, research centers, policy makers and investors.

- Henri Termeer, Chairman, President and CEO, Genzyme Corporation

“In this startling and cogent diagnosis of, and prognosis for, the biotechnology industry, Gary Pisano weaves a powerful economic argument that all is not well in biotechnology, an industry that should be the best hope for a better healthcare for us all. We in the industry need better to grapple with the challenges posed by this provocative book."

- Dr. Josh Boger, President and CEO of Vertex Pharmaceuticals

“The industrial structure that has arisen in the United States to develop and exploit the potential of biotechnology is widely regarded as extremely effective. But is it? Few biotech firms have made a profit, and the rate of introduction of new effective pharmaceuticals is not impressive. Gary Pisano’s fine study is the first to bring these ideas into the open, analyze them, and reflect on what they might mean for the future of biotechnology.”

- Richard Nelson, George Blumenthal Professor of International and Public Affairs, Business and Law, Emeritus, Columbia University

“Gary Pisano's analysis uncovers surprising facts about the industry's innovation power and productivity, challenging conventional wisdom. Science Business is refreshing and inspiring for anyone who is interested in the future success of biotechnology, including life science executives, investors, policy-makers and, most importantly, the patients who it has the potential to help the most"

- Dr. Daniel Vasella, Chairman & CEO, Novartis AG


Hero Quick Promo
Holiday Deals in Kindle Books
Save up to 85% on more than 1,000 Kindle Books. These deals are valid until November 30, 2015. Learn more

Product Details

  • Hardcover: 256 pages
  • Publisher: Harvard Business School Press; 1 edition (November 14, 2006)
  • Language: English
  • ISBN-10: 1591398401
  • ISBN-13: 978-1591398400
  • Product Dimensions: 1 x 6.2 x 9.2 inches
  • Shipping Weight: 1.2 pounds (View shipping rates and policies)
  • Average Customer Review: 4.2 out of 5 stars  See all reviews (13 customer reviews)
  • Amazon Best Sellers Rank: #170,557 in Books (See Top 100 in Books)

More About the Author

Discover books, learn about writers, read author blogs, and more.

Customer Reviews

Most Helpful Customer Reviews

32 of 35 people found the following review helpful By Elliot Kleiman on December 8, 2006
Format: Hardcover
Really just a wonderful introspective into the realm of the biotechnology sector. The writing style is excellent, entertaining, and very analytical. He does a fantastic job of illustrating the scientific challenges that make biotech unique. My favorite chapter in the first section (Section I) entitled, "The Science of the Business" was chapter 4, "Drug R&D and the Organizational Challenges". Here, he explains quite remarkably the differences between Drug R&D and other high tech industries, which he breaks down into the terms of "modularity" and "integrality"; just fantastic!

The second section (Section II) discusses, "The Business of the Science" which is equally interesting. In this section my favorite chapter was chapter 6, "The Performance of the Biotech Industry: Promise Versus Reality". Here he explores the financial and operational issues pertaining to the sector. I think manager/mba-types will like this second section. What I can say is that I learned quite a bit from this second section including info on raising capital (e.g. IPO, Partnering, licensing, etc.), and much about "the monetization of Intellectual Property".

Overall, I must say this is - IMHO - an unbiased expose on the biotech sector. In order to truly understand its history, its unique challenges, one should strongly consider this book b/c it hinges upon a number of terrific concepts that need to be discussed and illustrated for the unaware. The author assumes the reader knows nothing, so pretty much anyone with a penchant for biotech will enjoy. I learned a lot from this book and it was fun too. Five star rating all the way!
Comment Was this review helpful to you? Yes No Sending feedback...
Thank you for your feedback.
Sorry, we failed to record your vote. Please try again
Report abuse
7 of 7 people found the following review helpful By George Bush HALL OF FAME on June 10, 2010
Format: Hardcover
Biotechnology has sometimes been suggested as a source of high-paying jobs to replace the millions of manufacturing jobs lost to globalization and automation. Gary Pisano's (Harvard Business School professor) "Science Business" explores the topic of biotech's failure to meet these expectations. His conclusions stress a need for organizational structures and financing that place greater emphasis on long-term learning. The industry, in aggregate, has lost money over its then thirty-year lifespan, and has not brought improvements in drug R&D productivity.

In 'normal' R&D (eg. aircraft-, computer-chip design), years of experience provide an envelope of feasible trajectories. Not so in biotechnology - R&D there confronts fundamental questions that are difficult to answer and efforts to do so are likely to lead to more questions and involve quite long time horizons. Further, it is not possible to patent basic biomedical knowledge, and many researchers are reticent to become involved in private research where findings are kept secret instead of being published. A related problem is that the growing range of disciplines involved in biotechnology mandates either greater vertical integration (fewer, larger firms), or greater sharing of information. The former is not likely to be efficient, and the latter looked down upon by investors.

"Science Business" was published in 2006, and was predominantly limited to 2004 and prior data. Fortunately, an industry source [...] offers more recent information. Per that document, 30% of January, 2009 biotech companies had less than 6 months' cash on hand, and only 10% of the 370 public biotech companies have a positive income.
Read more ›
Comment Was this review helpful to you? Yes No Sending feedback...
Thank you for your feedback.
Sorry, we failed to record your vote. Please try again
Report abuse
6 of 6 people found the following review helpful By Jeff VINE VOICE on May 17, 2007
Format: Hardcover Verified Purchase
For my money, most business school professors write with a detached, dry atmosphere about business topics.

Not Gary Pisano!

He has a strong point of view that the ecosystem for biotech is not working well. His observations about why are right to the point and convincing.

His prescriptions are well worth considering.

If you're new to biotech, this is a great book to start out with. I would then proceed to Building Biotechnology, which is also a fine book.
Comment Was this review helpful to you? Yes No Sending feedback...
Thank you for your feedback.
Sorry, we failed to record your vote. Please try again
Report abuse
3 of 3 people found the following review helpful By Rob Hunter on July 26, 2007
Format: Hardcover
I found this book to be well-researched, current, and insightful. If you're at all interested in the biotech business, especially in starting a company or investing, read this book first. Pisano's narrative really helps one understand the foundations of the biotech industry, and sheds some light on what does, and doesn't, work within that industry. The fact that it's off the Harvard Business School Press gives it additional credibility, which is well deserved. A wealth of references, as well as a listing of the companies listed in the study, give the reader both a sense of the research that went into the book and a start on the search for more resources on the subject.
Comment Was this review helpful to you? Yes No Sending feedback...
Thank you for your feedback.
Sorry, we failed to record your vote. Please try again
Report abuse
7 of 9 people found the following review helpful By kerrjac on January 24, 2009
Format: Hardcover Verified Purchase
This book begins with the insight that good science is different from good business. Beyond this, I found the rest of the book kind of stale.

The author extensively discusses the idiosyncrasies of the biotech industry. He talks about the great amount of capital and trail-and-error required in drug development, supposedly with the intention of arguing that biotech is different from other sectors. However, I kept thinking, "But of course biotech is different from other sectors, it's a different sector." What this book lacked, I thought, were more comparisons and similarities between other areas of business. While biotech is the only industry that actively seeks drugs that hit molecular targets, it's not the only industry that heavily progresses through research and development. I was surprised that the author didn't tap the extensive history of R&D in other private sectors. After all, there's an array of specific examples to choose from, be it the microprocessor chip wars or the development of hybrid cars. Using lessons from those endeavors, and connecting them to biotech, I thought, could've been pretty novel.

Instead, the author rarely pulls insights from outside of the biotech industry, while maintaining that biotech is new, not fully developed, and can learn a lot from business. As such, the book has a very insular feel and seems very limited in scope.
1 Comment Was this review helpful to you? Yes No Sending feedback...
Thank you for your feedback.
Sorry, we failed to record your vote. Please try again
Report abuse

Most Recent Customer Reviews

Want to discover more products? Check out these pages to see more: gary pisano, novel business science